Imagine this scenario: A new investigational drug for the treatment of pancreatic cancer is in early phase III clinical trials. Phase II data published show a reasonable safety profile and early indication of effectiveness. There is a buzz in the clinical community, members of patient advocacy groups and a growing number pancreatic cancer blogs buzz with activity. Read this Whitepaper to find out more!
Read this paper about what the next five years will hold for the industry!
Most Recent Flipbooks
A lay summary for patients participating in clinical trials
Parexel expert Michelle Pietzak, MD reviews current findings and offers practical recommendations for gastrointestinal symptoms of COVID-19 and considerations for clinical trials.
In this article, experts from the Parexel Pediatric Collaborative Group review current findings and consider how sponsors can adapt their studies to changing conditions during COVID19.
This lay summary discusses what the guidance means for anyone in the USA who may be involved in or associated with a clinical trial.
In this article, Dr. Lazar Mandinov, Sr. Medical Director at Parexel, provides practical guidance for conducting CV clinical trials related to COVID-19.
Updated every day, in a single source
If regulatory and payer landscapes are so different, then why bring the two worlds together?
Parexel offers a complimentary, educational workshop custom built to your evidence and market access needs.